Elicio Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Elicio Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $2.30M | Mar 17, 2023 |
| FY2022 | Dec 31, 2021 | $28.31M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $2.88M | Mar 30, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($39.57M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($51.90M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($35.20M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($28.21M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($54.57M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($80.11M) | Mar 30, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($37.71M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($44.99M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($35.75M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($23.73M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($39.31M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($55.27M) | Mar 30, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.90M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $33.66M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $23.85M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $18.10M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $48.70M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $38.98M | Mar 30, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($36.95M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($37.07M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($32.69M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($22.18M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($52.64M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($22.89M) | Mar 30, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $87.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $66.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $654.0K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $382.0K | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $41.0K | Mar 30, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.86M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $28.18M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $27.15M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $22.66M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $96.51M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $47.35M | Mar 30, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.23M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $39.49M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $15.77M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $13.75M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $15.01M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $137.80M | Mar 30, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.64M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($11.31M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $11.37M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | ($102.15M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | ($74.54M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | ($90.45M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2019 | ($18.59M) | Mar 30, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($233.67M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($194.10M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($142.20M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($107.01M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($215.14M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($160.56M) | Mar 30, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.56M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $17.62M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $12.89M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.16M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $88.76M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $34.61M | Mar 30, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.00M | Mar 12, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (6) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (89) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | (5) | Mar 30, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (6) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (89) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | (5) | Mar 30, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 17.80M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 11.03M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 9.60M | Mar 31, 2025 |
| FY2024 | Jun 1, 2023 | 8.39M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 320,281 | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 29.96M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | 15.32M | Mar 30, 2022 |